What Happens When You Stop Taking Ozempic or Mounjaro?
It's one of the most common questions in every GLP-1 subreddit, doctor's office, and group chat: what happens to the weight when you stop? The short answer: most of it comes back without ongoing treatment. But newer 2026 maintenance data shows the choice is not simply full-dose forever or stop entirely. For managing side effects during treatment, see our separate guide.
What the Clinical Trials Show
Semaglutide: STEP 1 Extension & STEP 4
The STEP 1 extension study followed participants for one year after stopping semaglutide 2.4 mg:
The STEP 4 trial was even more direct. All participants took semaglutide for 20 weeks, then half switched to placebo:
Continued semaglutide
Lost an additional 7.9% body weight
Switched to placebo
Regained 6.9% body weight within 12 weeks
Tirzepatide: SURMOUNT-4
The picture with tirzepatide is similar, and a recent post-hoc analysis adds important detail:
- After 36 weeks of tirzepatide, participants achieved ~20.9% weight loss
- Those switched to placebo regained an average of 14.0% over the next 52 weeks
- A post-hoc analysis (JAMA Internal Medicine, February 2026) found 82% of participants who stopped tirzepatide regained 25% or more of their lost weight within one year
Cardiometabolic improvements (blood pressure, cholesterol, blood sugar) also reversed proportionally to weight regain, underscoring why the benefits of GLP-1 medications beyond weight loss depend on continued use.
2026 Maintenance Data: Oral Orforglipron After Injectable GLP-1s
The 2026 ATTAIN-MAINTAIN trial, led by Louis J. Aronne and colleagues and published in Nature Medicine, tested a different question: what happens if people who already lost weight on injectable therapy switch to an oral GLP-1 instead of stopping active treatment?
After tirzepatide
Orforglipron maintained 74.7% of prior weight reduction vs 49.2% with placebo over 52 weeks
After semaglutide
Orforglipron maintained 79.3% of prior weight reduction vs 37.6% with placebo over 52 weeks
The trial enrolled 376 participants from SURMOUNT-5, including 205 who had used tirzepatide and 171 who had used semaglutide. Participants on orforglipron also retained more cardiometabolic benefit, including waist circumference, blood pressure, blood sugar, triglycerides, and cholesterol improvements. This does not prove that every patient should switch drugs. It does show that maintenance is its own treatment phase, and that oral maintenance may become a real option for people who cannot or do not want to stay on injections.
SURMOUNT-MAINTAIN: Continuing Tirzepatide Preserved More Loss
A separate 2026 Lancet report from Deborah Horn and colleagues studied tirzepatide maintenance after a 60-week weight-loss period. At week 112, model-estimated weight change from baseline was −21.9% with continued maximum tolerated tirzepatide, −16.6% after reducing to 5 mg, and −9.9% after switching to placebo. Among participants who had reached a weight plateau, 77.5% on continued maximum tolerated dose, 42.4% on 5 mg, and 10.4% on placebo maintained at least 80% of the earlier body-weight reduction.
Why Does This Happen?
A systematic review and meta-analysis published in eClinicalMedicine(The Lancet, November 2025) identified the biological mechanisms behind “metabolic rebound”:
Obesity is a chronic condition with biological drivers. Removing the medication doesn't remove the underlying biology, it re-emerges.
We track GLP-1 prices so you don't have to
Get notified when providers drop prices or run sales. Our subscribers save first.
The Nuance: It's Not All-or-Nothing
While the average is two-thirds regain, individual variation is enormous. Some people maintain most of their loss. The factors that seem to matter:
Lifestyle changes built during treatment
- People who used the appetite suppression window to establish exercise habits and change their relationship with food tend to retain more
- The drug buys you time to build habits, the habits are what carry you
Length of treatment
- Longer treatment periods may lead to more durable metabolic adaptation
- Emerging evidence suggests staying on treatment for 12+ months creates more lasting changes than shorter courses
Maintenance as its own phase
- 2026 data supports maintenance as a separate treatment phase after initial weight loss
- The evidence now includes continued injectable therapy, lower-dose tirzepatide, and oral orforglipron after injectable treatment
The real question isn't “can I stop?”, it's “what's the minimum effective dose?” Most obesity medicine specialists now frame GLP-1s as chronic medications, similar to blood pressure drugs. You wouldn't stop your blood pressure medication because your numbers improved, the numbers improved because of the medication.
Maintenance Is Its Own Treatment Phase
The most important 2026 shift is framing. Weight loss and weight maintenance are related, but they are not the same phase of care. The first phase asks whether a drug can create meaningful weight reduction. The maintenance phase asks how much treatment is needed to preserve enough of that reduction to keep health benefits from reversing.
What the evidence supports now:
- Continuing effective GLP-1 therapy preserves more weight loss than stopping.
- Lower-intensity maintenance may preserve meaningful benefit for some people, but it preserved less than full continuation in SURMOUNT-MAINTAIN.
- Oral orforglipron preserved about three-quarters to four-fifths of prior injectable GLP-1 weight loss in ATTAIN-MAINTAIN, but it did not fully prevent regain.
The boundary is important. These trials inform conversations with clinicians. They do not provide a universal tapering, switching, or layering protocol for an individual patient.
Practical Strategies
If you're considering stopping or tapering your GLP-1 medication, or looking into more affordable options to continue treatment through a telehealth provider:
The Bottom Line
The evidence is unambiguous: most people regain a significant portion of lost weight after stopping GLP-1 medications.This doesn't mean the drugs don't work, it means they work while you take them, similar to most chronic disease medications.
The emerging consensus in obesity medicine is that for many patients, some form of ongoing treatment, whether continued injectable therapy, a maintenance strategy, or possibly an oral maintenance option, is the most realistic path to sustained results. If cost is a barrier to staying on treatment, there are proven ways to reduce GLP-1 costs.
We'll update this article as new data on tapering protocols and maintenance strategies emerges.
Sources
- Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance.” JAMA. 2021;325(14):1414–1425.
- Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes Obes Metab. 2022;24(8):1553–1564.
- Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4).” JAMA. 2024;331(1):38–48.
- “Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal: Post Hoc Analysis of SURMOUNT-4.” JAMA Intern Med. 2026.
- “Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.” eClinicalMedicine (The Lancet). 2025.
- Aronne LJ, et al. “Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.” Nature Medicine. 2026.
- Horn DB, et al. “Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN).” The Lancet. 2026.
Educational content only. This does not constitute medical advice. Always consult a qualified healthcare provider before changing your medication regimen. PeptidePub is an independent publication.